Project Grant R44HL184876
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $1.4M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Solana Beach, CA 92075, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded Prenosis, Inc. $1,218,102 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate the Heart Failure CardioScore, an artificial intelligence diagnostic tool for acute heart failure in emergency department patients. Prenosis will combine novel biomarkers and clinical data with machine learning to improve diagnostic and prognostic accuracy for acute heart failure, addressing the challenge...
- The National Heart, Lung, and Blood Institute awarded $920,616 to Vena Vitals Inc. on September 24, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop VeriSleep, a wearable device for continuous, non-invasive blood pressure monitoring during sleep as a cardiovascular biomarker. The project addresses the technological gap in continuous blood pressure measurement during sleep, where current intermittent cuff-based monitors leave lengthy unmonitored gaps despite the...
- The National Heart, Lung, and Blood Institute awarded Environment & Health Group Inc. $314,321 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop HeartSense.AI, a generative AI-driven mobile health solution for hypertension self-management in lower-income adults. The application describes an mHealth platform that integrates a generative AI model with home-based blood pressure monitoring, digital pill reminders, and non-physician-led telehealth to...
- The National Heart, Lung, and Blood Institute awarded Linshom Medical, Inc. $322,277 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct clinical evaluation of an alarm-activated detection system for early intervention of emerging respiratory decline using Linshom's FDA-cleared Continuous Predictive Respiratory Sensor (CPRS). The funding supports clinical development activities demonstrating the health economic value of the CPRS system, which...
- The National Heart Lung and Blood Institute awarded Fascia Sleep Incorporated $417,686 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate a wearable device for at-home sleep apnea diagnosis. Fascia is developing the Fascia Sleep Ecosystem, a home-based monitoring system integrating flexible electronics and fabric-based sensing technology into a wearable mask that captures clinical-grade physiological data comparable to Level II...
- The National Heart, Lung, and Blood Institute awarded Pulsentry, Inc. $309,198 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and prototype an automated detection system for cardiac tamponade using existing fingertip pulse oximeters. Pulsentry will develop machine learning algorithms that analyze pulse waveform perturbations to identify early signs of cardiac tamponade, a medical emergency caused by fluid or clot accumulation around the heart...
- The National Heart, Lung, and Blood Institute awarded $316,609 to Remplenish, Inc. on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel myofunctional nipple device for preventing obstructive sleep apnea in infants. The recipient will design and validate a low-risk, low-burden device that delivers myofunctional therapy—oropharyngeal exercises integrated into infant bottle feeding—as a non-invasive first-line treatment and preventive measure...
- The National Science Foundation (NSF) awarded a $305,000 STTR Phase I project grant to Sensvita Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project aims to develop a non-invasive radio frequency sensing technology for home-based monitoring of heart and lung function. The proposed system uses advanced sensing methods to measure critical physiological parameters without the need for skin contact or maintenance, improving the convenience, scalability,...
- The National Heart, Lung, and Blood Institute awarded Lynntech Inc. $319,607 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and demonstrate the feasibility of BreathWise, an AI-driven early-warning system for COPD exacerbations. BreathWise integrates multimodal physiological, behavioral, and environmental sensing with machine learning-based predictive analytics to identify COPD patients at imminent risk of exacerbation. The system continuously...